Unusual recurrence in advanced ovarian cancer after interval cytoreductive surgery and HIPEC

被引：0
|
作者：
Sonkusare, Shipra [1 ,2 ]
Prasannakumar, Somashekhar Sampige [3 ]
Ahuja, Vijay [1 ]
Kumar, Rohit [3 ]
机构：
[1] Aster Hosp Inc, Gynaecol Oncol, Bangalore, Karnataka, India
[2] All India Inst Med Sci Nagpur, Obstet & Gynaecol, Nagpur, Maharashtra, India
[3] Aster Hosp Inc, Surg Oncol, Bangalore, Karnataka, India
来源：
BMJ CASE REPORTS | 2025年 / 18卷 / 01期
关键词：
Cancer - see Oncology; Obstetrics and gynaecology; Cancer; Oncology; CHEMOTHERAPY; BEVACIZUMAB; DOXORUBICIN; PACLITAXEL; SURVIVAL; TRIAL;
D O I：
10.1136/bcr-2024-262137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ovarian cancer is the second most fatal gynaecological malignancy. The relapses after treatment of ovarian cancer usually occur within 2 years after completion of the first-line therapy. Recurrent ovarian cancer commonly presents as peritoneal surface deposits in the abdomen with or without ascites. A delayed relapse presenting as a solitary lesion in the urinary bladder wall is unusual in patients treated for advanced ovarian cancer. We report the successful management of a case of solitary metastasis of ovarian cancer in the urinary bladder wall, which occurred more than 6 years after achieving a complete remission state.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] The place of secondary complete cytoreductive surgery in advanced ovarian cancer
    Jennifer, Asmar
    Iptissem, Naoura
    Aurelie, Revaux
    Philippe, Kadhel
    Marc, Ayoubi Jean
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2020, 41 (03)
  • [42] Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer
    Fotiou, Stelios
    Aliki, Tserkezoglou
    Petros, Zarganis
    Ioanna, Stauropoulou
    Konstantinos, Velentzas
    Vasiliki, Michalaki
    George, Creatsas
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 178 - 182
  • [43] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at first recurrence, or later?
    Gonzalez Bayon, L.
    Steiner, M. A.
    Vasquez Jimenez, W.
    Asencio, J. M.
    Alvarez de Sierra, P.
    Atahualpa Arenas, F.
    Rodriguez del Campo, J.
    Garcia Sabrido, J. L.
    EJSO, 2013, 39 (10): : 1109 - 1115
  • [44] Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer
    Paris, Ida
    Cianci, Stefano
    Vizzielli, Giuseppe
    Fagotti, Anna
    Ferrandina, Gabriella
    Alletti, Salvatore Gueli
    Costantini, Barbara
    Cosentino, Francesco
    Capoluongo, Ettore
    Pasqualoni, Mariangela
    Scambia, Giovanni
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2019, 35 (01) : 370 - 374
  • [45] Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer
    Llueca, Antoni
    Climent, Maria Teresa
    Escrig, Javier
    Carrasco, Paula
    Serra, Anna
    Gomez-Quiles, L.
    Jativa, R.
    Cebrian, G.
    Bosso, V
    Villarin, A.
    Maiocchi, K.
    Delgado-Barriga, K.
    Rodrigo-Aliaga, M.
    Ruiz, N.
    Herrero, C.
    Frances, A.
    Beato, I
    Ferrer, C.
    Aracil, J. P.
    Boldo, E.
    Boldo, A.
    Adell, R.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [46] Predicting the Outcome of Cytoreductive Surgery for Advanced Ovarian Cancer A Review
    Ibeanu, Okechukwu A.
    Bristow, Robert E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 : S1 - S11
  • [47] The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
    Zhang, Guyu
    Zhu, Yimin
    Liu, Chongdong
    Chao, Guangming
    Cui, Ran
    Zhang, Zhenyu
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [48] Survival Outcome After Interval Cytoreductive Surgery in Advanced-Stage Epithelial Ovarian Carcinoma: A Tertiary Care Centre Experience
    Nath, Aswathy G.
    Rema, P.
    Suchetha, S.
    Sivaranjith, J.
    Krishna, Jagathnath
    Vijayashanti, T.
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (02)
  • [49] Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
    Spiliotis, J.
    Halkia, E.
    Lianos, E.
    Kalantzi, N.
    Grivas, A.
    Efstathiou, E.
    Giassas, S.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1570 - 1575
  • [50] Thirty-Day Mortality After Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the Elderly
    Thrall, Melissa M.
    Goff, Barbara A.
    Symons, Rebecca Gaston
    Flum, David R.
    Gray, Heidi J.
    OBSTETRICS AND GYNECOLOGY, 2011, 118 (03) : 537 - 547
12345